Changes in normal liver and spleen volume after radioembolization with 90Y-resin microspheres in metastatic breast cancer patients: Findings and clinical significance

CardioVascular and Interventional Radiology

Volumn 34, Issue 5, 2011, Pages 964-972

  Paprottka, Philipp M ^a   Schmidt, G P ^a   Trumm, C G ^a   Hoffmann, R T ^a   Reiser, M F ^a   Jakobs, T F ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Arterial intervention; Breast; Embolization; Endovascular treatment; Interventional oncology; Liver; Radioembolization

Indexed keywords

CAPECITABINE; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; NAVELBINE; RADIOACTIVE MICROSPHERE; RESIN MICROSPHERE Y 90; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; BREAST CANCER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; FEMALE; HUMAN; LIVER METASTASIS; LIVER WEIGHT; MALE; PORTAL VEIN; PRIORITY JOURNAL; RADIOEMBOLIZATION; SPLEEN WEIGHT; TREATMENT OUTCOME; TUMOR VOLUME; VEIN DIAMETER;

ADULT; AGED; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; ORGAN SIZE; RADIOPHARMACEUTICALS; SPLEEN; YTTRIUM RADIOISOTOPES;

EID: 80555155537     PISSN: 01741551     EISSN: 1432086X     Source Type: Journal    
DOI: 10.1007/s00270-011-0217-8     Document Type: Article

References (49)

1. Angitapalli R, Litwin AM, Kumar PR et al (2009) Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. Oncology 76(5):363-368
2. Atalay G, Biganzoli L, Renard F et al (2003) Clinical outcome of breast cancer patients with liver metastases alone in the anthra-cycline-taxane era: a retrospective analysis of two prospective, randomised metastatic breast cancer trials. Eur J Cancer 39(17): 2439-2449 (Pubitemid 37340158)
3. Ayav A, Habib N, Jiao LR (2005) Portal hypertension secondary to Yttrium microspheres: an unknown complication. J Clin Oncol 23(32):8275-8276 (Pubitemid 46211568)
4. Bangash AK, Atassi B, Kaklamani V et al (2007) Y radio-embolization of metastatic breast cancer to the liver: toxicity, imaging response, survival. J Vasc Interv Radiol 18(5):621-628 (Pubitemid 46661173)
5. Berstein LM, Kovalevskij AY, Poroshina TE et al (2007) Signs of proinflammatory/genotoxic switch (adipogenotoxicosis) in mammary fat ofbreast cancer patients: role ofmenopausal status, estrogens and hyperglycemia. Int J Cancer 121(3):514-519 (Pubitemid 46986483)
6. Burstein HJ, Keshaviah A, Baron AD et al (2007) Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-over-expressing metastatic breast cancer: the trastuzumab and vino-relbine or taxane study. Cancer 110(5):965-972 (Pubitemid 47312860)
7. Campbell AM, Bailey IH, Burton MA (2000) Analysis of the distribution of intra-arterial microspheres in human liver fol-lowing hepatic yttrium-90 microsphere therapy. Phys Med Biol 45(4):1023-1033 (Pubitemid 30196393)
8. Campbell AM, Bailey IH, Burton MA (2001) Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol 46(2):487-498 (Pubitemid 32148511)
9. Chia SK, Speers CH, D'Yachkova Y et al (2007) The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer. Cancer 110(5):973-979 (Pubitemid 47312861)
10. Coldwell DM, Kennedy AS, Nutting CW (2007) Use ofyttrium-90 microspheres in the treatment of unresectable hepatic metas-tases from breast cancer. Int J Radiat Oncol Biol Phys 69(3): 800-804 (Pubitemid 47418394)
11. Cosimelli M, Golfieri R, Cagol PP et al (2010) Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unre-sectable, chemotherapy refractory colorectal liver metastases. Br J Cancer 103(3):324-331
12. Dawson LA, Mc Ginn CJ, Normolle D et al (2000) Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 18(11): 2210-2218 (Pubitemid 30350212)
13. Eichbaum MH, Kaltwasser M, Bruckner T, de Rossi TM, Sch-neeweiss A, Sohn C (2006) Prognostic factors for patients with liver metastases from breast cancer. Breast Cancer Res Treat 96(1):53-62
14. Er O, Frye DK, Kau SW et al (2008) Clinical course of breast cancer patients with metastases limited to the liver treated with chemotherapy. Cancer J 14(1):62-68
15. Gaba RC, Riaz A, Lewandowski RJetal (2010) Safety of yttrium-90 microsphere radioembolization in patients with biliary obstruction. J Vasc Interv Radiol 21(8):1213-1218
16. Gennari A, Conte P, Rosso R, Orlandini C, Bruzzi P (2005) Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies. Cancer 104(8):1742-1750 (Pubitemid 41437440)
17. Gulec SA HR, Pennington K et al (2008) A Phase II clinical trial of yttrium-90 microspheres selective internal radiation treatment with concomitant chemotherapy as a front-line treatment in patients with colorectal cancer liver metastases: evaluation of objective tumor response by quantitative FDG-PET/CT imaging. In: Abstract presented at the Society of Surgical Oncology 61st annual cancer symposium, Chicago
18. Gulec SA, Pennington K, Hall M, Fong Y (2009) Preoperative Y-90 microsphere selective internal radiation treatment for tumor downsizing and future liver remnant recruitment: a novel approach to improving the safety of major hepatic resections. World J Surg Oncol 7:6
19. Ingold JA, Reed GB, Kaplan HS, Bagshaw MA (1965) Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med 93:200-208
20. Jakobs TF, Hoffmann RT, Fischer T et al (2008) Radioemboli-zation in patients with hepatic metastases from breast cancer. J Vasc Interv Radiol 19(5):683-690
21. 90yttrium microspheres. Dig Dis Sci 53(9):2556-2563
22. 90Y micro-spheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys 60(5):1552-1563 (Pubitemid 39601873)
23. Kennedy AS, Coldwell D, Nutting C et al (2006) Resin Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys 65(2):412-425
24. Kennedy A, Nag S, Salem R et al (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68(1):13-23 (Pubitemid 46589861)
25. Kulik LM, Atassi B, van Holsbeeck L et al (2006) Yttrium-90 microspheres (Thera Sphere) treatment of unresectable hepato-cellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94(7):572-586 (Pubitemid 44851918)
26. 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40(3):583-592 (Pubitemid 28104228)
27. Lim L, Gibbs P, Yip D et al (2005) A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemo-therapy. BMC Cancer 5:132
28. Liu DM, Salem R, Bui JT, Courtney A, Barakat O, Sergie Z, Atassi B, Barrett K, Gowland P, Oman B, Lewandowski RJ, Gates VL, Thurston KG, Wong CY (2005) Angiographic con-siderations in patients undergoing liver-directed therapy. J Vasc Interv Radiol 16(7):911-935 (Pubitemid 40993515)
29. Macdonald JS (1999) Adjuvant therapy of colon cancer. CA Cancer J Clin 49(4):202-219
30. Marn CS, Andrews JC, Francis IR, Hollett MD, Walker SC, Ensminger WD (1993) Hepatic parenchymal changes after intraarterial Y-90 therapy: CT findings. Radiology 187(1): 125-128 (Pubitemid 23097872)
31. Marty M, Cognetti F, Maraninchi D et al (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23(19): 4265-4274 (Pubitemid 46207001)
32. Moroz P, Anderson JE, Van Hazel G, Gray BN (2001) Effect of selective internal radiation therapy and hepatic arterial chemo-therapy on normal liver volume and spleen volume. J Surg Oncol 78(4):248-252 (Pubitemid 33097055)
33. Morris-Stiff G, Tan YM, Vauthey JN (2008) Hepatic complica-tions following preoperative chemotherapy with oxaliplatin or irinotecan for hepatic colorectal metastases. Eur J Surg Oncol 34(6):609-614 (Pubitemid 351671976)
34. Murata Y, Ogawa Y, Saibara T et al (2000) Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol Rep 7(6):1299-1304
35. Murthy R, Nunez R, Szklaruk J, Erwin W, Madoff DC, Gupta S, Ahrar K, Wallace MJ, Cohen A, Coldwell DM, Kennedy AS, Hicks ME (2005) Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics 25(Suppl 1):S41-55 (Pubitemid 41686061)
36. 90yttrium microsphere therapy for unre-sectable hepatocellular carcinoma. Hum Pathol 40(1):125-134
37. Pentheroudakis G, Fountzilas G, Bafaloukos D et al (2006) Metastatic breast cancer with liver metastases: a registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treat 97(3):237-244 (Pubitemid 43945754)
38. Phillips R, Karnofsky DA, Hamilton LD, Nickson JJ (1954) Roentgen therapy of hepatic metastases. Am J Roentgenol Radium Ther Nucl Med 71(5):826-834
39. Qayyum A, Lee GK, Yeh BM, Allen JN, Venook AP, Coakley FV (2007) Frequency of hepatic contour abnormalities and signs of portal hypertension at CT in patients receiving chemotherapy for breast cancer metastatic to the liver. Clin Imaging 31(1):6-10 (Pubitemid 44960640)
40. Rubbia-Brandt L, Audard V, Sartoretti P et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15(3):460-466 (Pubitemid 38444550)
41. Sharma RA, Van Hazel GA, Morgan B et al (2007) Radioemb-olization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluoro-uracil, and leucovorin chemotherapy. J Clin Oncol 25(9): 1099-1106 (Pubitemid 46596762)
42. Stubbs RS (2006) Portal hypertension and liver surgery following selective internal radiation therapy with Yttrium microspheres. J Clin Oncol 24(9):e15
43. Stubbs RS, Wickremesekera SK (2004) Selective internal radia-tion therapy (SIRT): a new modality for treating patients with colorectal liver metastases. HPB (Oxford) 6(3):133-139 (Pubitemid 39248172)
44. Tehranipour N, AL-N A, Canelo R et al (2007) Concordant F-18 FDG PET and Y-90 Bremsstrahlung scans depict selective delivery of Y-90-microspheres to liver tumors: confirmation with histopathology. Clin Nucl Med 32(5):371-374 (Pubitemid 46659171)
45. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
46. Van den Eynde M, Flamen P, El Nakadi I et al (2008) Inducing resectability of chemotherapy refractory colorectal liver metas-tasis by radioembolization with yttrium-90 microspheres. Clin Nucl Med 33(10):697-699
47. Vauthey JN, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mor-tality after surgery for hepatic colorectal metastases. J Clin Oncol 24(13):2065-2072 (Pubitemid 46622116)
48. Wharton JT, Delclos L, Gallager S, Smith JP (1973) Radiation hepatitis induced by abdominal irradiation with the cobalt 60 moving strip technique. Am J Roentgenol Radium Ther Nucl Med 117(1):73-80
49. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK (2007) Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94(3):274-286 (Pubitemid 46423843)